Cancer Research The Future of Cancer Research: Science and Patient Impact  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 46, 1603-1607, April 1, 1986]
© 1986 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rubinstein, L. J.
Right arrow Articles by Bona, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rubinstein, L. J.
Right arrow Articles by Bona, C. A.

Regulation of Myeloma Growth in Mice by Antigen and Regulatory Idiotopes1

Leonard J. Rubinstein and Constantin A. Bona2

Department of Microbiology, Mount Sinai School of Medicine, New York, New York 10029

The effect of antigen, activation of normal A48Id+ B-cell clones, and monoclonal antibodies sharing A48-UPC10 regulatory idiotopes on the in vivo growth of spleen adapted ABPC48 myeloma cells has been examined. Immunogenic doses of bacterial levan have no detectable effects, whereas tolerogenic doses substantially delay the growth of the myeloma. The activation of normal A48Id+ B cell clones also has no apparent effect on the growth of the ABPC48 myeloma cells. Among a panel of 15 monoclonal antibodies expressing A48-UPC10 regulatory idiotopes and expressing VH genes derived from the VH441-4 germ line gene family, 5 were able to provide a long lasting but not definitive idiotype specific protection against the ABPC48 myeloma cells.

1 Supported by Grant IM-275 from the American Cancer Society.

2 To whom requests for reprints should be addressed, at Annenberg 16–60, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029.

Received 6/11/85. Revised 10/25/85. Accepted 12/11/85.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1986 by the American Association for Cancer Research.